You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
NMDA Receptor Subtype Selective Modualtors as Alzheimer's Disease Therapeutics
SBC: NEUROP, INC. Topic: NIADESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a devastating neurodegenerative disorder. One of the few drugs used to treat AD is memantine, which inhibits N-methyl-d-aspartate receptors (NMDARs), glutamate receptor subtypes found at nearly all vertebrate excitatory synapses. NMDARs are critically involved in many aspects of nervous system function, including learning and me ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Enable Early and Sensitive In Vivo Detection of Liver Metastasis by Protein-based
SBC: INLIGHTA BIOSCIENCES L.L.C. Topic: NCIDESCRIPTION (provided by applicant): The major barriers limiting the application of MRI to detect small liver lesions and metastasis at the early stage and patient selection for targeted therapy based on molecular imaging of disease biomarkers, are due tothe lack of desired MRI contrast agents capable of enhancing the contrast between normal liver tissues and tumors with high relaxivity, tumor tar ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics
SBC: PPI PHARMACEUTICALS, LLC Topic: NCIDESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Rapid, Accurate, and Low-Cost Stool Clostridium difficile Genetic Test
SBC: LENIMA FIELD DIAGNOSTICS LLC Topic: NIAIDDESCRIPTION (provided by applicant): Clostridium difficile (CD) is a bacterium causing diarrhea and other intestinal problems linked to 14,000 annual deaths in the US. CDI is an antibiotic-associated infection as well as a health-care-associated infection.Current CDI diagnosis relies on CD toxins enzyme immunoassay (EIA) together with antigen (GDH) EIA. Although stool toxin EIA is specific and rel ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A Millimeter-wave Tunable Cavity for Ultra-sensitive Solids and Liquids DNP-NMR at Low Budget
SBC: DOTY SCIENTIFIC, INC. Topic: NIA? DESCRIPTION (provided by applicant): NMR is probably the most powerful and widely used analytical technique for structure determination and function elucidation of molecules of all types, but it suffers from low sensitivity, particularly for insoluble biological macromolecules. Dynamic Nuclear Polarization (DNP) with Magic Angle Spinning (MAS) has recently demonstrated S/N gains exceeding t ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Small Molecule Inhibitors of HIV1 Nef Virulence Factor for Treatment of HIV_AIDS
SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC. Topic: NIGMSDESCRIPTION: While HIV/AIDS can be managed with antiretroviral drugs that block viral replication, these agents do not clear the virus and require life-long drug administration with associated risks of cumulative toxicity and drug resistance. Recently, wediscovered a completely new class of compounds that interfere with the HIV-1 virulence factor, Nef. This viral protein is critical to HIV-1 repli ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT
SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC. Topic: NHLBIWe have discovered the first-ever inhibitors of PF4, a platelet protein central to the pathophysiology of heparin induced thrombocytopenia (HIT). Heparin is a naturally-occurring anticoagulant that prevents the formation of clots and extension of existingclots within the vasculature, and major medical applications of heparin include dialysis, cardiac catheterization, and cardiopulmonary bypass sur ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A Wireless Device to Monitor and Track Fluid Consumption in At-Risk Older Adults
SBC: Smart Activity of Daily Living, LLC Topic: NINRDESCRIPTION (provided by applicant): The long term goal of the proposed project by Smart Activities of Daily Living, LLC (Smart ADLs) is to develop a device (the Smart Cup) that will improve the health of older adults by managing nutrition using smart health technology. Malnutrition (under nutrition) is a common geriatric syndrome found in older adults across the care continuum. Older adults accou ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Robotic whole organism HTS platform for drug discovery and development
SBC: Luminomics Inc. Topic: NCATSDESCRIPTION (provided by applicant): Our goal is to create a compact, affordable, fully automated, screening system for large-scale drug 2 testing in living small animal disease models (e.g., worms, flies, and fish). Modern drug discovery is 3 driven by high-throughput screening (HTS) systems that have the capacity to evaluate large chemical 4 compound 'libraries'. The majority of hits ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of Peptide Antibiotic Nucleic Acids
SBC: NUBAD LLC Topic: NIAIDDESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health